Search Results

You are looking at 1 - 10 of 18 items for :

  • "psychosocial factors" x
Clear All
Full access

Jamie M. Jacobs, Molly E. Ream, Nicole Pensak, Lauren E. Nisotel, Joel N. Fishbein, James J. MacDonald, Joanne Buzaglo, Inga T. Lennes, Steven A. Safren, William F. Pirl, Jennifer S. Temel and Joseph A. Greer

. Table 2. Multiple Regression Illustrating Relationships Between Psychosocial Factors and QoL Discussion We examined adherence, symptom burden, and QoL in patients with diverse malignancies who were prescribed oral therapy and enrolled in a randomized

Full access

Neal J. Meropol, Joanne S. Buzaglo, Jennifer Millard, Nevena Damjanov, Suzanne M. Miller, Caroline Ridgway, Eric A. Ross, John D. Sprandio and Perry Watts

Although clinical trial research is required for the development of improved treatment strategies, very few cancer patients participate in these studies. The purpose of this study was to describe psychosocial barriers to clinical trial participation among oncologists and their cancer patients. A survey was distributed to all medical oncologists in Pennsylvania and a subset of their patients. Relevant background information and assessment of practical and psychosocial barriers to clinical trial participation were assessed. Among 137 oncologists and 170 patients who completed the surveys, 84% of patients were aware of clinical trials, and oncologists and patients generally agreed that clinical trials are important to improving cancer treatment. However, oncologists and patients were more likely to consider clinical trials in advanced or refractory disease. When considering 7 potential barriers to clinical trials, random assignment and fear of receiving a placebo were ranked highly by both patients and oncologists. Patients identified fear of side effects as the greatest barrier to clinical trial participation, whereas oncologists ranked this psychosocial barrier as least important to their patients. Overall, the study found that although oncologists and patients are aware of clinical trials and have favorable attitudes toward them, psychosocial barriers exist for patients that may impact participation in clinical trials. Furthermore, important discrepancies exist between the perceptions of oncologists and those of patients regarding what the psychosocial barriers are. We concluded that characterizing oncologist and patient perceived barriers can help improve communication and decision making about clinical trials, such that participation may be optimized.

Full access

Dayna S. Early and Darrell M. Gray II

CRC if they had a family history of CRC, a personal history of colon polyps, or had undergone their first colonoscopy. Psychosocial Factors Psychosocial factors may reduce compliance with CRCS. Patients report psychosocial factors such as fear

Full access

Lois Ramondetta

of plans to initiate additional therapy. The benefit and risk of any treatment is affected by a great number of variables, including age, socioeconomic factors, tobacco use, and psychosocial factors. Discussions relating to cytotoxic treatment for

Full access

Bianca Lewis, Caitlin R. Meeker, Elizabeth Handorf, Kelly Filchner, Rino Seedor, Jennifer S. Winn, Lori J. Goldstein and Efrat Dotan

analysis, we sought to describe the psychosocial profile of older community patients with MBC, and investigate the correlation between psychosocial factors and presence of other GA abnormalities. Methods: This study included hands-on experience

Full access

Jennifer A. Ligibel and Crystal S. Denlinger

dysfunction in cancer survivors should focus on the level of activity (past and present), the impact of cancer therapy, and sexual concerns or symptoms. Comorbidities, risk factors, and psychosocial factors should be considered. The NCCN Guidelines feature

Full access

Abraham S. Kanate, Miguel-Angel Perales and Mehdi Hamadani

intensive and life-altering therapy such as allo-HCT. 45 In fact, psychosocial factors such as relationship status and somatic symptoms have been associated with transplant outcomes. 46 In our experience, prior history of noncompliance, lack of motivation

Full access

Elizabeth A. Nardi, James McCanney, Katy Winckworth-Prejsnar, Alyssa A. Schatz, Kerin Adelson, Marcus Neubauer, Mary Lou Smith, Ronald Walters and Robert W. Carlson

(Millwood) 2016 ; 35 : 401 – 406 . 9. Kimmel PL . Psychosocial factors in adult end-state renal disease patients treated with hemodialysis: correlates and outcomes . Am J Kidney Dis 2000 ; 35 : 132 – 140 . 10. Adelson KB Velji S

Full access

Daniel C. McFarland, Heather Polizzi, John Mascarenhas, Marina Kremyanskaya, Jimmie Holland and Ronald Hoffman

for breast cancer: a review of stress pathways and biological mediators . Brain Behav Immun 2009 ; 23 : 159 – 166 . 10. Costanzo ES Lutgendorf SK Sood AK . Psychosocial factors and interleukin-6 among women with advanced ovarian cancer

Full access

Crystal S. Denlinger, Jennifer A. Ligibel, Madhuri Are, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Lee W. Jones, Allison King, Grace H. Ku, Elizabeth Kvale, Terry S. Langbaum, Mary S. McCabe, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Mary Ann Morgan, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, M. Alma Rodriguez, Kathryn J. Ruddy, Tara Sanft, Paula Silverman, Sophia Smith, Karen L. Syrjala, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Nicole R. McMillian and Deborah A. Freedman-Cass

for PTSD, so that clinicians are alert to the disease-related and other physical and psychosocial factors that can play a role in the disorder (see SANXDE-B, page 721). In addition, the guidelines now allow for further evaluation, referral, and